The effect of Galvus (vildagliptin) on post-prandial endothelial function and post-prandial hypertriglyceridaemia in individuals with Type 2 diabetes and fasting hypertriglyceridaemia, treated with statins.

Associate Professor Seng Khee Gan0 个研究点目标入组 20 人开始时间: 2011年9月16日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Outpatients with Type 2 diabetes on metformin treatment only (at doses 500mg to 1000mg twice daily).
•HbA1c < 8%.
•Already treated with a statin for at least 6 weeks with LDL cholesterol<2.5 mmol/L.
•Hypertriglyceridaemia (Triglycerides > 1.7 mmol/L) on a random blood sample.

•Treatment with other oral diabetes medications other than metformin.
•Treatment with insulin or exenatide.
•HbA1c > 8%.
•Treatment with fibrates.
•Premenopausal females. Menopause is defined as 12 consecutive months without menstruation. If menopausal status is in question, a follicle-stimulating hormone (FSH) level of > 30 mIU/ml must be documented.
•Primary dyslipidaemia, including the E2/E2 genotype.
•Type III dyslipedaemia.
•Uncontrollable hypertension: resting BP > 150/90.
•Consumption of > 30g alcohol per week.
•Tobacco smoking.
•Significantly abnormal liver function (ALT or AST > 3 times ULN).
•Creatine kinase > 3 x ULN.
•Creatinaemia (> 150 micromols).
•Macroproteinuria.
•Significantly abnormal thyroid function.
•Atrial fibrillation or significant dysrythmia.
•Cardiovascular event in the last 6 months.
•Gastric disorders.
•Any other serious medical / systemic illness (e.g cancer).
•Use of steroids or other medications that may affect lipid metabolism.
•Psychiatric illness.
•Allergies to eggs, cream, milk.
•Likelihood of poor compliance to the study.
•Likelihood of not completing the study.

发起方

Associate Professor Seng Khee Gan